The Paediatric HIV Treatment Initiative welcomes this important step towards closing the treatment gap for children with HIV Infants and young children living with HIV will finally have access to an ...
GlaxoSmithKline (GSK) will partner with VBI Vaccines to study VBI’s LPV™ Platform, a formulation and process designed to help develop vaccines and biologics with improved stability and potency. The ...
Sanofi Pasteur has chosen VBI's LPV™ technology to develop a more stable formulation of a key Sanofi Pasteur vaccine candidate. The collaboration will leverage VBI's LPV™ technology, which allows for ...
Children living with HIV have to take multiple different antiretroviral (ARV) pills or syrups twice a day, while most adults in South Africa have been offered one pill once a day regimen for around a ...
The US FDA has approved an innovative formulation, Lopinavir/ritonavir (LPV/r) 40mg/10mg oral pellets, for paediatric specific treatment of HIV/Aids in infants. Cipla Medpro CEO, Paul Miller Developed ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
Licence will support the work of the recently launched Paediatric HIV Treatment Initiative (PHTI) to Develop Better Adapted Medicines for Children Living with the Virus GENEVA, December 1, 2014 – On ...
Washington, D.C.--June 8, 2015-- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the announcement of tentative approval by the U.S. Food and Drug Administration of a new antiretroviral ...
Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration's (FDA) tentative ...
Children living with HIV have to take multiple different antiretroviral (ARV) pills or syrups twice a day, while most adults in South Africa have been offered one pill once a day regimens for around a ...
Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration's (FDA) tentative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results